Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Adiutrix Therapeutics
Profile last edited on: 8/25/25      CAGE: 9REA9      UEI: SECASJ6KJBY5

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
2023
First Award
2024
Latest Award
2024
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

79 Washington Pl Apt 4f
New York, NY 10011
   N/A
   N/A
   N/A
Location: Single
Congr. District: 10
County: New York

Public Profile

A biotechnology company indicated as focused on the development of first-in-class anti-fibrotic therapeutics. Adiutrix Therapeutics is developing a novel targeted therapy for the lung-stiffening disease known as idiopathic pulmonary fibrosis.

Extent of SBIR involvement

User Avatar
Phase I Awards
1
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$350,000
Phase II Dollars
$0
Total Awarded
$350,000

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2024 1 NIH $350,000
Project Title: Platform technology to identify and develop first-in-class anti-fibrotic therapeutics through inhibition of collagen CP4H

Key People / Management

  Ronald W Lennox

  Randi B Silver

Company News

There are no news available.